Archives
-
ATRA Reverses Cisplatin-Associated PARP Resistance
2026-09-03
A 2025 study in Molecular Cancer Therapeutics shows that all-trans retinoic acid can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer models. Sequential cisplatin treatment followed by niraparib maintenance with ATRA improved tumor control and survival in preclinical systems, while implicating ALDH1A1, NAMPT, PARP1, CHEK1, and intracellular NAD+ as components of the resistant state.
-
AZD1390: ATM Kinase Inhibitor Workflow
2026-09-03
AZD1390 enables concentration-controlled ATM inhibition for radiation, replication-stress, and glioblastoma models. Its strongest use-case is a mechanistic workflow that connects double-strand-break signaling with emerging REV1–DHX36 control of G-quadruplex DNA tolerance.
-
AZD1390 ATM Kinase Inhibitor Workflow
2026-09-02
AZD1390 enables precise interrogation of ATM-dependent DNA damage signaling and radiation response in glioma and lung cancer models. This workflow combines validated radiosensitization conditions with exploratory assays for G-quadruplex replication stress, helping distinguish checkpoint failure from direct repair defects.
-
Sulfisomidine: A Matrix-Aware Research Framework
2026-09-02
Sulfisomidine, also known as sulfamethin, is more than a sulfonamide antibacterial: it is a mechanistic probe for folate biology, hPON1 inhibition, and transformation-product research. This guide connects enzyme assay design with environmental fate analysis to improve interpretation and reproducibility.
-
Geneticin, G-418 Sulfate: Selection Guide
2026-09-01
Geneticin, G-418 Sulfate (SKU A2513) provides selective pressure for cells carrying a neomycin resistance gene and can support defined antiviral experiments involving Dengue virus serotype 2. Its working concentration must be optimized by cell type and assay; the dossier range is not a substitute for a cell-line-specific kill curve or cytotoxicity control.
-
Platelet Extravasation into Tumors: Molecular Control
2026-09-01
The reference study establishes that platelet entry into tumors is an actively regulated process rather than passive leakage from abnormal vessels. It identifies stromal CXCL12–CXCR4 signaling, platelet FAK and PECAM-1, and distinct granule-release pathways as separable controls of platelet trafficking, vascular integrity, and tumor growth.
-
Matrine: A Mechanism-to-Assay Research Map
2026-08-31
Matrine is a Sophora-derived alkaloid with interconnected anticancer, apoptotic, and anti-inflammatory effects. This evidence-led guide separates established observations from mechanistic hypotheses and translates recent thymoma findings into better assay-selection decisions.
-
(S)-(+)-Dimethindene maleate: Practical Guide
2026-08-31
(S)-(+)-Dimethindene maleate is a research tool for evaluating M2 muscarinic and histamine H1 receptor antagonism when subtype-aware assay design is required. This dossier-based guidance covers preparation, controls, and interpretation; the compound is not intended for diagnostic, clinical, or medical use.
-
In Vitro Drug Response Metrics in Cancer
2026-08-30
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of an anticancer response. This framework supports more informative experimental designs by requiring researchers to consider response magnitude, mechanism, and timing rather than relying on a single viability endpoint.
-
Early Life Adversity, Oxytocin, and Innate Defense
2026-08-29
A 2026 Communications Biology article links early life adversity with impaired looming-evoked defensive behavior in mice and identifies deficient oxytocin signaling in the superior colliculus as a mechanistic contributor. The study combines developmental stress modeling, behavioral analysis, receptor knockdown, circuit investigation, and intranasal oxytocin rescue to connect early experience with innate threat processing.
-
Propidium Iodide in Placental Immune Assays
2026-08-28
Propidium iodide is more than a routine DNA intercalating dye: it can define the membrane-integrity boundary in placental trophoblast–T-cell models. This guide explains how to pair PI with apoptosis, proliferation, and immune-differentiation readouts while avoiding misleading biological conclusions.
-
Catalpol, Glycolysis, and Src Signaling in Fibrosis
2026-08-28
The reference study identifies a mechanistic link between hepatic stellate-cell glycolysis and EphA2/FAK/Src signaling in experimental liver fibrosis. Its combination of disease models, metabolic readouts, and target-engagement assays suggests that catalpol acts upstream of this pathway, while also highlighting important limits for translation beyond toxin-induced and cell-culture models.
-
Tofacitinib (CP-690550) in RA Macrophage Assays
2026-08-27
Tofacitinib (CP-690550) is a practical tool for connecting JAK/STAT cytokine signaling with inflammatory macrophage phenotypes and mitochondrial stress. This workflow translates recent rheumatoid arthritis findings into dose-ranging, pathway, and metabolic assays that distinguish broad cytokine signaling blockade from metabolism-only interventions.
-
MK-4827 Workflow for PARP Inhibition Studies
2026-08-27
Build sharper DNA damage repair inhibition assays with MK-4827 (Niraparib), from BRCA-genotype profiling through sequential cisplatin and maintenance designs. This workflow also shows how to troubleshoot solubility, exposure timing, and PARP pharmacodynamic readouts for cancer research.
-
3-Deazaadenosine: From Methylation to Translation
2026-08-26
A translational framework for using 3-Deazaadenosine as an S-adenosylhomocysteine hydrolase inhibitor in methylation, inflammation, and preclinical antiviral research—while separating target-specific evidence from broader metabolic perturbation.